Drug intelligence / Profile preview

acrixolimab

Development stage: Phase 2
Lead developer: Y Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Acrixolimab (YBL-006) is a monoclonal antibody developed by Y Biologics that targets LIGHT (Tumor Necrosis Factor Ligand Superfamily Member 14, TNFSF14). LIGHT is a pro-inflammatory cytokine that plays a significant role in the regulation of immune responses and is implicated in the pathogenesis of various inflammatory and autoimmune conditions. By binding to LIGHT, acrixolimab is intended to modulate immune activity and reduce inflammation. According to company pipeline information, the drug is currently in Phase 2 clinical development for the treatment of autoimmune diseases.

Other names: acrixolimab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on acrixolimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acrixolimab.

Explore the full profile